TheraRadar
← Back
Data updated: Mar 29, 2026

JUBILANT

OncologyRespiratoryMetabolic
Specialty

JUBILANT is a specialty pharmaceutical company focused on Oncology, Respiratory, Metabolic. Key products include DRAX EXAMETAZIME.

1978
Since
8
Drugs
-
Trials
2
Approved (2yr)

Key Drugs

DRAX EXAMETAZIME
technetium tc-99m exametazime kit
Immunology
2 indications · 2017
RUBY-FILL
rubidium chloride rb-82
Cardiovascular
Na+/K+ pump 1 indications · 2016

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

SODIUM IODIDE I 131 2025-06-12
DRAXIMAGE MDP-10 2025-05-22
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 33%
2 drugs
Respiratory 33%
2 drugs
Metabolic 17%
1 drugs
Infectious Disease 17%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Respiratory
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic
GSK big-pharma
Infectious Disease, Respiratory, Oncology
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic